Objective To explore the feasibility of a novel multimodal executive function intervention in school-aged children with complex congenital heart disease (cCHD). Design Single-centre, single-blinded, randomised-controlled 8-week multimodal personalised executive function intervention (E-Fit) study.
Outcomes were measured throughout the intervention, post-intervention (T1) and at 4-month follow-up (T2). Participants Children 10 to 12 years (M=11.0, SD=0.9) with cCHD without a genetic diagnosis with infant open-heart surgery and reported difficulties (T-scores ≥60) on any of the summary scales of the parent- or teacher-reported Behavior Rating Inventory for Executive Function (BRIEF).
Interventions Children with cCHD were randomly assigned to one of two groups: the intervention or the control group. The 8-week intervention was multimodal including three modalities: (1) computerised executive function (EF) training 3×20 min/week with CogniFit; (2) a weekly, remote standardised 1:1 individual EF strategy coaching; (3) analogue games played at convenience.
The control group completed activity logs. Feasibility measures Acceptability: Acceptance and Feasibility Scale (AFS) and coach-rated engagement during coaching sessions.
Demand: Number of completed computerised training, strategy coaching and analogue game sessions.
Study design and purpose: a feasibility assessment of a multimodal EF intervention for school-aged children with complex congenital heart disease
Executive function deficits are highlighted as a long-term neurodevelopmental concern in this population.
While exploratory signals appeared favorable for certain domains, formal efficacy conclusions cannot be drawn.
Future work should address recruitment strategies to achieve more representative samples.
This should be mitigated in future trials through stricter blinding procedures where feasible.
If subsequent trials confirm efficacy, E-Fit could represent a scalable approach to supporting EF and social functioning in this high-risk group.
High retention and successful delivery of core components suggest practicality for future testing in larger samples or multi-centre settings.
These signals warrant careful evaluation in adequately powered efficacy trials.
Specific numerical values for adjusted Hedge’s g estimates and exact BRIEF subscale changes were not provided here.